{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Gut Check Project","title":"LDN Unlocked: Journey to Wellness with Low Dose Naltrexone","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/bf50121c\"></iframe>","width":"100%","height":180,"duration":5939,"description":"DEEP DIVE into (LDN) Low Dose Naltrexone with Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPh\n\n\nLow Dose Naltrexone (LDN) Clearly from the adjectives it’s a “non standard” dosage from what naltrexone was originally intended. But why?\n\nLDN is a method (with EXTENSIVE data) of finding benefits to healing from certain issues that have often left people hopeless. \n\nWeight management, nerve damage, palsy, autoimmune thyroid disorders, cancer, chronic fatigue syndrome, chronic pain,Crohn’s diease, fibromyalgia, PTSD, multiple sclerosis, myalgic encephalomyelitis.\n\nThe GCP welcomes three experts and Clinical Compounding Pharmacists to share with you their knowledge and experience in helping people find comfort and happiness again in their lives! Sebastion Denison, RPh, Andy Komuves, RPh, & Joe Bertrand, RPh join Ken & Eric to discuss the hype and evidence around LDN.\n\n\n\n\nREFERENCES \nhttps://a4pc.org/  \nhttps://www.pccarx.com/Resources/FindACompounder\nhttps://www.achc.org/compounding-pharmacy/\n \nhttps://ldnresearchtrust.org/  \nhttps://ldnresearchtrust.org/2024_LDN_Guides\nhttps://ldnresearchtrust.org/sites/default/files/2024-02/Dosing-Guide-2024_0.pdf  \ncurrent dosing recommendations\n \n \n \nhttps://www.jpsmjournal.com/article/S0885-3924%2803%2900139-8/fulltext  \nUltra low dose early info\n \nPurdue had Oxycontin and the combination was used clinically and was pursued, then Oxytrex was the trade name-2005 phase 3 trials,  by a company Pain Therapeutics-but did not launch or fully launch\nTROXYCA® ER is a Pfizer product in 2016 (higher doses)\nhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207621s004lbl.pdf\n ","thumbnail_url":"https://img.transistorcdn.com/ex7NNhaU7W8TdddovkZRJNai7yaCmJL072o2Y-Z4cg4/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQ4NzYvMTY4ODc2/ODY0Mi1hcnR3b3Jr/LmpwZw.webp","thumbnail_width":300,"thumbnail_height":300}